Curix, part of the Demcon Group, is working on groundbreaking technology for the treatment of neurological diseases

Curix, part of the Demcon group, is developing groundbreaking technology for the treatment of life-threatening and debilitating neurological diseases. This new technology makes it possible to temporarily open the blood-brain barrier, addressing one of the biggest challenges in neurology. With this technology, drugs for brain tumors and neurodegenerative conditions, such as Alzheimer's and Parkinson's disease, can be delivered more efficiently. The participation of Twinning Participaties allows Curix to develop an injector system suitable for initial clinical studies in humans. “Our ultimate goal is to contribute to the development of improved treatments for neurological diseases”, says Peter Frinking, managing director and chief scientific officer at Curix. Read more...